Skip to main content Skip to search Skip to main navigation

PIC/S: Guidance on Remote Assessments

PIC/S has published two guidance documents for inspectors: "Guidance on Remote Assessments" (PI 056-1) and "Aide Memoire on Remote Assessments" (PI 057-1). These documents will enter into force on 1 January 2025.

The PIC/S states that the remote assessment and hybrid inspection will have a place in an inspector‘s toolkit beyond the pandemic.

They soon will be available in our GMP knowledge portal, the GMP Compliance Adviser.

Guidance on remote assessments
The guidance distinguishes between fully interactive remote assessments, partially interactive remote assessments, desktop assessments, and hybrid inspections.
It covers the logistics and the technical requirements for remote inspections.

A feasibility check for a remote inspection using a risk assessment is mandatory. Factors to be considered include:

  • Previous inspection history
  • Activities carried out at site
  • Length of time since last on-site inspection
  • Information relating to the site from any regulatory authority / source
  • Changes since last inspection
  • Internet connectivity of site and of inspectors

Documentation requirements are also given. For example, the GMP certificate should clearly state whether the assessment/inspection was performed remotely, on-site or hybrid.

Aide Memoire on remote inspections
The Aide Memoire provides best practices and summaries for preparing and conducting remote assessments and post-inspection activities. It also provides prompts and questions to guide users through these processes.
Issues raised include, for example:

  • Pre-inspection teleconference with the site
  • Secure platform for sharing documents
  • Connectivity test
  • Need for an independent translator
  • Daily tentative schedule to ensure the availability of subject matter exterts (SMEs)
  • Site tours?
  • What type of document will be issued after the remote assessment

Source:

PIC/S: News

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

ICH: Updated Q9(R1) Briefing Pack

ICH: Updated Q9(R1) Briefing Pack

The ICH has fully revised the Q9(R1) Briefing Pack (March/April 2026) to align with the updated ICH Q9 guideline.
Read more
EMA: New Plans for the EU GMP Guide

EMA: New Plans for the EU GMP Guide

EMA published the GMDP Inspectors Working Group’s new 2026-2028 work plan and its 2025 annual report.
Read more
EMA: Pharmaceutical Quality System (PQS) Effectiveness Pilot Project

EMA: Pharmaceutical Quality System (PQS) Effectiveness Pilot Project

EMA launched a pilot under which EEA GMP inspectors will assess how sites demonstrate the effectiveness of their pharmaceutical quality system for risk-based change management, and whether the EEA GMP certificate could serve as the main evidence of this effectiveness.
Read more
EMA: Updated Guideline on Active Substance Chemistry

EMA: Updated Guideline on Active Substance Chemistry

The EMA has updated guidance on the information required for the manufacture and control of active substances used in medicinal products, with a 1 September 2026 date of application.
Read more
EMA: Q&A on the Implementation of 3DP Technology for Solid Oral Dosage Forms

EMA: Q&A on the Implementation of 3DP Technology for Solid Oral Dosage Forms

EMA added a new GMP/Q&A section on its website and published a dedicated Q&A document on 3D printing (3DP) for solid oral dosage forms.
Read more
Microbiological Monitoring – Sources of Contamination

Microbiological Monitoring – Sources of Contamination

All pharmaceutical dosage forms must be manufactured under controlled microbiological conditions. This requires microbial monitoring. This applies not only to sterile manufacturing, but also to facilities that manufacture non-sterile products.
Read more
Previous
Next